376270 — HEM Pharma Income Statement
0.000.00%
Last trade - 00:00- KR₩144bn
- KR₩140bn
- KR₩15bn
Annual income statement for HEM Pharma, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 1,857 | 3,668 | 5,344 | 15,067 |
| Cost of Revenue | ||||
| Gross Profit | 487 | 623 | 801 | 1,622 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 12,812 | 16,911 | 17,110 | 22,754 |
| Operating Profit | -10,955 | -13,243 | -11,766 | -7,687 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -10,919 | -13,009 | -11,667 | -7,611 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -10,919 | -13,009 | -11,667 | -7,646 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -10,919 | -13,009 | -11,667 | -7,646 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -10,919 | -13,009 | -11,667 | -7,646 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -1,571 | -1,871 | -1,638 | -1,099 |
| Dividends per Share |